# ZOSTAVAX® in Renal Transplant Patients

> **NCT01137669** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 34 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Live attenuated herpes zoster vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01137669
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137669, "ZOSTAVAX® in Renal Transplant Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01137669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*